معرفی
Andrew Zloza, MD, PhD, is an Assistant Professor in the Department of Internal Medicine at Rush Medical College, Rush University. He holds advanced degrees including an MD from Rush Medical College, a PhD from Rush Graduate College, and a BS from Illinois Institute of Technology. His research focuses on cancer immunotherapy, particularly leveraging oncolytic viruses, vaccines, and immune checkpoint inhibitors to modulate tumor microenvironments. Key areas include viral-based therapies for melanoma and breast cancer, influenza vaccine applications in oncology, and combination treatments with radiation and checkpoint inhibitors. His work bridges preclinical models and clinical trials, such as the CAPRA study evaluating Coxsackievirus A21 with pembrolizumab in advanced melanoma. Dr. Zloza also explores immune signaling pathways (e.g., NKG2D, TGFβ, interferons) and their roles in tumor immunity. His studies highlight the potential of microbial-based therapies and viral infections in enhancing antitumor responses.
Education:
- MD, Rush Medical College
- PhD, Rush Graduate College
- BS, Illinois Institute of Technology
Research Interests:
- Oncolytic virus development and clinical translation
- Immune checkpoint modulation and combination therapies
- Microbial interactions with cancer progression
- Immunomodulatory effects of viral infections
- Preclinical models of melanoma and breast cancer
Recent Work Trends: Over 30 publications since 2017 reflect a focus on translational cancer immunology, with emphasis on viral therapies, immune signaling, and clinical trial outcomes. His articles highlight synergistic effects of radiation with oncolytic viruses and the role of interferons in cancer immunity. Ongoing projects include evaluating dengue virus-based oncolytics and influenza vaccine-induced tumor microenvironment remodeling.
Awards: Not explicitly listed in the provided texts.
Advising & Grants: No specific student names or grant details provided, but his work involves collaborative clinical trials (e.g., CAPRA study) and preclinical research programs.
Labs/Teams: Likely involved in Rush University's cancer research initiatives and collaborations with pharmaceutical partners (e.g., ONC201 drug trials).
